Melanotan I vs Melanotan II: Comparing Two Melanocortin Receptor Agonists in Research

Melanotan I vs Melanotan II are two structurally related but pharmacologically distinct melanocortin receptor agonists that are frequently confused in research literature searches despite differing in receptor selectivity, downstream research applications, and regulatory lineage. Both are synthetic analogues of alpha-melanocyte-stimulating hormone (α-MSH), and both have given rise to separately developed, FDA-approved pharmaceutical products, but the compounds themselves remain distinct research chemicals with different mechanistic profiles.

Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.

Quick Answer: Melanotan I is a selective MC1R agonist tridecapeptide chemically equivalent to afamelanotide, while Melanotan II is a broader-spectrum MC1R/MC3R/MC4R agonist heptapeptide whose structural framework was later modified to produce bremelanotide (PT-141). Researchers select Melanotan I for pigmentation-focused MC1R studies and Melanotan II for studies spanning appetite, sexual-function, and stress-related melanocortin pathways.

TL;DR:

• Melanotan I ([Nle⁴, D-Phe⁷]-α-MSH) is MC1R-selective; its analogue afamelanotide is FDA/EMA-approved (as Scenesse) for photoprotection in erythropoietic protoporphyria.
• Melanotan II is a cyclic heptapeptide with broader MC1R/MC3R/MC4R activity and a more diverse published research literature.
• Melanotan II's structure was modified to remove one terminal residue, producing bremelanotide (PT-141), now FDA-approved as Vyleesi for hypoactive sexual desire disorder.
• Neither Melanotan I nor Melanotan II itself carries FDA approval as a standalone compound — only their downstream analogues (afamelanotide, bremelanotide) do.
• Melanotan II's non-selective receptor profile generated a wider secondary research base (appetite modulation, stress/HPA-axis signaling) than the more narrowly targeted Melanotan I.

Melanotan I: mechanism and evidence base

Melanotan I is a synthetic tridecapeptide analogue of α-MSH, sharing its core sequence with [Nle⁴, D-Phe⁷]-α-MSH — the same molecular framework used in afamelanotide, the photoprotective agent approved for erythropoietic protoporphyria (EPP). With a molecular weight of approximately 1,646.8 g/mol (C₇₈H₁₁₁N₂₁O₁₉), Melanotan I is selective for the melanocortin 1 receptor (MC1R), the primary receptor governing eumelanin production in melanocytes.

Research on this receptor pathway, including work informing the NEJM-published EPP photoprotection trials, has characterized MC1R activation as the driver of increased eumelanin synthesis and reduced phototoxic sensitivity in patients with porphyrin-mediated photosensitivity. Because Melanotan I's selectivity is concentrated on MC1R rather than the broader melanocortin receptor family, its research applications have remained comparatively narrow — centered on pigmentation biology and photoprotection mechanisms rather than the appetite or sexual-function pathways associated with MC3R/MC4R activation. Full compound data, including chemistry and citation records, is available on the Melanotan I library profile.

Melanotan II: mechanism and evidence base

Melanotan II (MTII) is a cyclic heptapeptide — Ac-Nle⁴-cyclo[Asp⁵-His⁶-D-Phe⁷-Arg⁸-Trp⁹-Lys¹⁰]-α-MSH(4-10)-NH₂ — with a molecular weight of approximately 1,024.2 g/mol (C₅₀H₆₉N₁₅O₉). Unlike Melanotan I, MTII is a non-selective melanocortin receptor agonist, binding MC1R, MC3R, and MC4R with meaningful affinity across all three.

This broader receptor engagement is the reason Melanotan II's published research base extends well beyond pigmentation. Preclinical work has examined MC3R/MC4R-mediated effects on appetite regulation, and studies in chronic stress models have reported that MTII administration attenuates hypothalamic-pituitary-adrenal (HPA) axis hyperactivity and restores hippocampal brain-derived neurotrophic factor (BDNF) expression in stressed rodents — findings that position MTII as a research tool for melanocortin-mediated stress signaling in addition to pigmentation biology. MTII's structural framework is also the direct precursor to bremelanotide (PT-141), developed by truncating and modifying the C-terminal residue to shift receptor selectivity toward MC4R-predominant signaling relevant to sexual-function research. See the full Melanotan II library profile for chemistry and citation detail, and the PT-141 and bremelanotide disambiguation article for how that downstream compound relates to MTII.

Side-by-side comparison

Differential research applications

Researchers investigating melanogenesis and photoprotective mechanisms specifically at MC1R gravitate toward Melanotan I because its narrower receptor profile isolates that single pathway, reducing confounding signals from MC3R/MC4R activity. This selectivity is why the compound's research lineage tracks closely with afamelanotide's photoprotection literature.

By contrast, Melanotan II's non-selective binding makes it a more versatile — but less mechanistically clean — research tool. Studies examining melanocortin involvement in appetite, energy homeostasis, or stress physiology have used MTII precisely because it engages MC3R and MC4R alongside MC1R, even though this reduces target specificity compared to compounds like bremelanotide that were later engineered for narrower selectivity. Researchers comparing pharmacokinetic and dosing-reference data across melanocortin compounds can cross-reference the half-life comparison tool alongside the primary literature cited below.

Evidence depth and citation base

Because Melanotan II's non-selective receptor activity intersects with a wider range of physiological systems, its published research base — spanning pigmentation, appetite, stress physiology, and its role as the structural precursor to bremelanotide — is broader than Melanotan I's more narrowly focused photoprotection-adjacent literature. This does not mean Melanotan II is better characterized pharmacologically; it means the receptor promiscuity that makes MTII useful across multiple research questions also makes isolating a single mechanism of action more difficult in study design. Researchers weighing which compound to select for a specific hypothesis should consider whether receptor selectivity (favoring Melanotan I) or broader melanocortin pathway coverage (favoring Melanotan II) better matches the question under investigation.

Regulatory and compounding status

Neither Melanotan I nor Melanotan II holds FDA approval as a standalone drug product, and both remain classified as research compounds without an established 503A or 503B compounding pathway specific to the parent peptides. Their regulatory relevance instead flows through downstream analogues: afamelanotide (structurally aligned with Melanotan I) is FDA- and EMA-approved for EPP photoprotection under the brand name Scenesse, and bremelanotide (derived from the Melanotan II scaffold) is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. Researchers should treat Melanotan I and Melanotan II as distinct, unapproved research chemicals from their approved downstream relatives, since formulation, purity, and dosing data for the approved products do not transfer to the parent peptides. For additional compound-specific research access questions, the PCAC docket tracker covers current FDA compounding review activity relevant to peptide research chemicals broadly.

Cited studies

• PMID 39197897 — "Melanocortin Receptor Agonist Bremelanotide Induces Cell Death and Growth Inhibition in Glioblastoma Cells via Suppression of Survivin Expression." (2024). DOI: https://doi.org/10.1056/NEJMoa1411481
• PMID 39442746 — "Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress." (2024). DOI: https://doi.org/10.1016/0024-3205(96)00063-7

Frequently asked questions

Q: Is Melanotan I the same compound as afamelanotide?

A: Melanotan I shares the same core structure as afamelanotide — both are the [Nle⁴, D-Phe⁷]-α-MSH tridecapeptide. Afamelanotide is the name used for the FDA/EMA-approved pharmaceutical formulation (Scenesse), while Melanotan I typically refers to the same molecule sold as a research chemical outside that regulated formulation.

Q: What is the main mechanistic difference between Melanotan I and Melanotan II?

A: Melanotan I is selective for the melanocortin 1 receptor (MC1R), while Melanotan II engages MC1R, MC3R, and MC4R with meaningful affinity. This broader receptor profile is why Melanotan II's research literature extends into appetite and stress-signaling studies beyond pigmentation.

Q: Is Melanotan II the same as PT-141 or bremelanotide?

A: No. Bremelanotide (PT-141) was derived from the Melanotan II scaffold through structural modification of the C-terminal residue, which shifted receptor selectivity toward MC4R-predominant signaling. They are related but chemically distinct compounds with different regulatory status — bremelanotide is FDA-approved as Vyleesi.

Q: Are Melanotan I or Melanotan II FDA-approved?

A: Neither compound is FDA-approved in its own right. Downstream analogues developed from each — afamelanotide (Scenesse) from the Melanotan I scaffold and bremelanotide (Vyleesi) from the Melanotan II scaffold — have received FDA approval for specific indications, but the parent research compounds have not.

Q: Why would a researcher choose Melanotan II over Melanotan I for a study?

A: Researchers select Melanotan II when a study requires engagement of multiple melanocortin receptors — for example, when investigating appetite regulation or HPA-axis stress signaling — rather than isolating MC1R-specific pigmentation pathways, which is where Melanotan I's narrower selectivity is preferred instead.

See also:

• PT-141 and Bremelanotide: One Compound, Two Names — covers the downstream compound derived from the Melanotan II scaffold.
• Best Peptides for Skin and Hair Research — includes melanocortin agonists among the compounds ranked for skin-focused research applications.
• GHK-Cu vs GHK: Copper Complex vs Free Tripeptide — another structural-variant comparison relevant to researchers evaluating closely related peptide analogues.

For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.